middle.news
FDA Greenlights Arovella’s ALA-101 for First Human Trials in Blood Cancers
9:22am on Thursday 29th of January, 2026 AEDT
•
Biotechnology
Read Story
FDA Greenlights Arovella’s ALA-101 for First Human Trials in Blood Cancers
9:22am on Thursday 29th of January, 2026 AEDT
Key Points
FDA accepts IND application for ALA-101
Phase 1 trials to target CD19-positive non-Hodgkin’s lymphoma and leukaemia
Regulatory approval streamlines trial initiation in Australia and the U.S.
IND framework supports future CAR-iNKT therapies including ALA-105
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
AROVELLA THERAPEUTICS (ASX:ALA)
OPEN ARTICLE